USING AUTOMATED INSULIN DELIVERY (‘ARTIFICAL PANCREAS’) FOR GLYCAEMIC MANAGEMENT IN PEOPLE WITH TYPE 1 DIABETES AND END STAGE KIDNEY DISEASE ON HAEMODIALYSIS.

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

Presented the abstract " "
(Abstract co-author(s): )

Back

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.

E-Poster Format Requirements

PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos

E-Poster

Abstract Title *

USING AUTOMATED INSULIN DELIVERY (‘ARTIFICAL PANCREAS’) FOR GLYCAEMIC MANAGEMENT IN PEOPLE WITH TYPE 1 DIABETES AND END STAGE KIDNEY DISEASE ON HAEMODIALYSIS.

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

The title will not be accepted if it exceeds 25 words.
Type in CAPITAL LETTERS.
Lowercase may be used for abbreviations only, for example, mRNA.

Co-author 1

Panagiotis pavlou panagiotis.pavlou@kcl.ac.uk King's College London Diabetes London United Kingdom -

Co-author 2

Lalantha Leelarathna lalantha.leelarathna@nhs.net Imperial College Diabetes London United Kingdom -

Co-author 3

Thomas Johnston thomas.johnston1@nhs.net Guy's and St Thomas Hospital Diabetes London United Kingdom -

Co-author 4

Rebecca Hyslop rebecca.hyslop1@nhs.net Guy's and St Thomas Hospital Diabetes London United Kingdom -

Co-author 5

Monika Reddy monika.reddy@nhs.net Imperial Diabetes London United Kingdom -

Co-author 6

Parizad Avari p.avari@nhs.net Imperial Diabetes London United Kingdom -

Co-author 7

Rachael Tan r.tan4@nhs.net King's College Hospital Diabetes London United Kingdom -

Co-author 8

Sufyan Hussain sufyan.hussain@kcl.ac.uk King's College London Diabetes London United Kingdom -

Co-author 9

Janaka Karalliedde j.karalliedde@kcl.ac.uk King's College London Diabetes London United Kingdom *

Co-author 10

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15

Introduction

Managing diabetes in end-stage kidney disease (ESKD) in people with type 1 diabetes on haemodialysis (HD) presents unique challenges. There is an unmet need for adaptable therapies in this high risk group. who are prone to glycaemic variability and hypoglycaemia. Automated insulin delivery (AID) systems ('artificial pancreas') may be effective as they can adjust insulin delivery dynamically in line with continuous glucose monitoring data, however there are no studies in HD. This study aimed to evaluate real-world use of AID in HD

Methods

We studied six individuals (3 females, 3 males) with type 1 diabetes (mean duration 32.3 years) and ESKD on stable thrice-weekly HD at three London hospitals. Mean age was 40.3 years. Participants used commercially available AID systems: Medtronic MiniMed™ 780G, Omnipod 5, or Tandem T-Slim, based on preference and centre experience. Data were collected from CGM and AID platforms and electronic health records. Pre-AID data were from at least 14 days, and post-AID data from a minimum of 8 weeks. The primary outcome was change in time-in-range (TIR; 3.9–10 mmol/L). Secondary outcomes included time below range (TBR), time above range, glucose variability (GV), mean glucose, HbA1c, total daily insulin (TDI), bodyweight, and HD day-specific TIR and TDI.

Results

Over a mean follow-up of 5.2 months, mean TIR improved from 34.8% to 58.8% (p=0.006), “Very High” range decreased from 37.2% to 13.3% (p=0.007), and HbA1c fell from 9.2% to 77.4 to 7.4% (p=0.03). GV, mean glucose, and HD-day TIR also significantly improved. TDI decreased, though modest TDI changes on HD days were not statistically significant.

Conclusion

AID use in people with type 1 diabetes and ESKD on HD improved glycaemic control. Further larger-scale studies are needed in this high risk and clinically challenging cohort.

Kewords